News in Brief
Pharmacology - Oct 23
Novartis announces European Medicines Agency (EMA) has granted orphan drug designation for iptacopan (LNP023) in IgA nephropathy (IgAN)
Novartis announces European Medicines Agency (EMA) has granted orphan drug designation for iptacopan (LNP023) in IgA nephropathy (IgAN)
wire - news in brief
Category
Results 151 - 200 of 431.
Novartis investigational novel STAMP inhibitor asciminib (ABL001) meets primary endpoint of Phase III chronic myeloid leukemia study
At primary analysis, ASCEMBL met its primary endpoint of significant superiority in major molecular response rate at 24 weeks for asciminib (ABL001) vs.
At primary analysis, ASCEMBL met its primary endpoint of significant superiority in major molecular response rate at 24 weeks for asciminib (ABL001) vs.
In the body, so-called programmed cell death prevents cells with irreparable damage from surviving and turning into cancer cells. In the "EMBO Journal", researchers at the University of Basel's Biozentrum, report how a certain protein variant thwarts the self-destruction and thus promotes the growth of breast cancer cells.
The pornographic sequences broadcast live on the web feature between 300,000 and 500,000 people - the vast majority of them women - for a largely male clientele of at least 500 million followers.
Thanks to technology from ETH spin-off Neustark, concrete recycling plants can store carbon dioxide over the long term.
Novartis provides update on Phase III study evaluating investigational spartalizumab (PDR001) in combination with Tafinlar + Mekinist in advanced melanoma
Phase III COMBI-i trial did not meet primary endpoint for patients with advanced BRAF V600-mutated melanoma Tafinlar + Mekinist remains an effective treatment option based on previously reported larg
Phase III COMBI-i trial did not meet primary endpoint for patients with advanced BRAF V600-mutated melanoma Tafinlar + Mekinist remains an effective treatment option based on previously reported larg
When our DNA breaks, cells use the so-called homologous recombination pathway to accurately repair the break, so that DNA is fixed and no mutations are introduced during the repair process. When multiple DNA molecules are broken, the recombination factors use a smart strategy to join only the DNA pieces originating from the same DNA molecules.
FDA approves Novartis Kesimpta (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis
Kesimpta delivers powerful efficacy with a favorable safety profile and can be self-administered at home, addressing significant unmet needs for people living with relapsing forms of multiple scleros
Kesimpta delivers powerful efficacy with a favorable safety profile and can be self-administered at home, addressing significant unmet needs for people living with relapsing forms of multiple scleros
An interactive video game created by researchers and students in the College of Humanities (CDH) and UNIL Gamelab, in collaboration with the Initiative for Media Innovation (IMI) and Le Temps, allows
Two EPFL students have compared the ability of a forest in Vaud Canton to protect against avalanches before and after it was ravaged by fire in 2018.
UZH Introduces Five New University Research Priority Programs
The University of Zurich is introducing five new University Research Priority Programs focusing on equal opportunities, human reproduction, rare diseases, digital religions and basic principles of learning.
The University of Zurich is introducing five new University Research Priority Programs focusing on equal opportunities, human reproduction, rare diseases, digital religions and basic principles of learning.
Summer series: science as a vocation. Kumar Varoon Agrawal, a tenure-track assistant professor who holds the Gaznat Chair for Advanced Separations at EPFL Valais-Wallis, is developing advanced membranes for the molecular separation of industrial product streams, mainly for CO2 capture.
FDA Approves Roche’s ENSPRYNG for Neuromyelitis Optica Spectrum Disorder (NMOSD)
First and only FDA-approved subcutaneous treatment option for anti-aquaporin-4 antibody positive NMOSD that can be self-administered by a person with NMOSD or a caregiver every four weeks First and o
First and only FDA-approved subcutaneous treatment option for anti-aquaporin-4 antibody positive NMOSD that can be self-administered by a person with NMOSD or a caregiver every four weeks First and o
IOR takes part in innovative project for real-time Covid-19 testing device
SARS-CoV-2 virus analysis involves complex procedures and requires long waiting times.
SARS-CoV-2 virus analysis involves complex procedures and requires long waiting times.
Summer series: Careers in research. Florian Breider, who heads EPFL's Central Environmental Laboratory (CEL), knew from a young age that he wanted to become a scientist.
The software platform, NeuroKey, interfaces with multiple brain signal acquisition sources and devices, extending the reach of brain-computer interface applications GENEVA, SWITZERLAND & SALT LAKE CITY, UTAH, USA - The Wyss Center for Bio and Neuroengineering has granted a worldwide license to Blackrock Microsystems to commercialize its neural signal processing and decoding software platform for research and clinical applications.
Pushing the boundaries of implantable neuro-device development Today the Wyss Center for Bio and Neuroengineering, Geneva, Switzerland and OSYPKA AG/OSYPKA Medtec, Rheinfelden, Germany and Longmont,
FDA approves Roche’s Evrysdi (risdiplam) for treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older
In two clinical trials, Evrysdi improved motor function in people living with SMA over a broad spectrum of ages and levels of disease severity, including Types 1, 2, and 3 SMA Evrysdi helped infants
In two clinical trials, Evrysdi improved motor function in people living with SMA over a broad spectrum of ages and levels of disease severity, including Types 1, 2, and 3 SMA Evrysdi helped infants
On behalf of the Federal Office of Public Health, the Swiss Tropical and Public Health Institute (Swiss TPH) analysed the health consequences of the hot and dry summer of 2019 and compared it to the hot summers of 2003, 2015 and 2018. The results were published this week in the report "Health effects of heat in Switzerland and the importance of prevention measures".
Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis
Ofatumumab is a targeted B-cell therapy that delivers superior efficacy with a similar safety profile when compared with teriflunomide, a commonly prescribed oral treatment for multiple sclerosis 1
Ofatumumab is a targeted B-cell therapy that delivers superior efficacy with a similar safety profile when compared with teriflunomide, a commonly prescribed oral treatment for multiple sclerosis 1
Novartis announces Kymriah meets primary endpoint at interim analysis of pivotal study in follicular lymphoma
Global ELARA trial demonstrated clinically meaningful benefit in patients with relapsed or refractory (r/r) follicular lymphoma (FL) as measured by complete response rate Kymriah previously receive
Global ELARA trial demonstrated clinically meaningful benefit in patients with relapsed or refractory (r/r) follicular lymphoma (FL) as measured by complete response rate Kymriah previously receive
Novartis Cosentyx receives EU approval for first-line systemic treatment in pediatric psoriasis
EU approval is based on two Phase III studies showing Cosentyx provides fast and strong skin clearance, along with significant improvement in quality of life and a favorable safety profile 1 Modera
EU approval is based on two Phase III studies showing Cosentyx provides fast and strong skin clearance, along with significant improvement in quality of life and a favorable safety profile 1 Modera
Novartis receives Piqray approval in Europe - the first and only targeted medicine for HR+/HER2- advanced breast cancer with a PIK3CA mutation
Piqray (alpelisib) is the only treatment approved specifically to address PIK3CA mutation, underscoring Novartis commitment to reimagining cancer care Approval based on SOLAR-1 Phase III trial showing Piqray plus fulvestrant nearly doubled median PFS (11.0 vs.
Piqray (alpelisib) is the only treatment approved specifically to address PIK3CA mutation, underscoring Novartis commitment to reimagining cancer care Approval based on SOLAR-1 Phase III trial showing Piqray plus fulvestrant nearly doubled median PFS (11.0 vs.
Olga Fink develops artificial intelligence algorithms for industrial assets, rolling stock and power plants.
Immunoprotein impairs Sars-Cov-2
An international team with researchers of the Institute of Virology and Immunology (IVI) of the University of Bern and the Swiss Federal Food Safety and Veterinary Office (FSVO) showed that an endogenous protein prevents the virus from fusing with host cells.
An international team with researchers of the Institute of Virology and Immunology (IVI) of the University of Bern and the Swiss Federal Food Safety and Veterinary Office (FSVO) showed that an endogenous protein prevents the virus from fusing with host cells.
In Agatha Christie's novel The Pale Horse, the victims die of thallium poisoning.
News in Brief
Pharmacology - Oct 23
Novartis announces European Medicines Agency (EMA) has granted orphan drug designation for iptacopan (LNP023) in IgA nephropathy (IgAN)
Novartis announces European Medicines Agency (EMA) has granted orphan drug designation for iptacopan (LNP023) in IgA nephropathy (IgAN)